Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Child's Nervous System
Published in: Child's Nervous System 6/2012

01-06-2012 | Case Report

Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report

Authors: Caterina Cerminara, Valentina Bagnolo, Francesco De Leonardis, Antonella Coniglio, Denis Roberto, Eliana Compagnone, Paolo Curatolo

Published in: Child's Nervous System | Issue 6/2012

Login to get access

Excerpt

Hepatocellular adenoma is a rare, benign liver tumour diagnosed predominantly in women on oral contraceptive therapy [1, 2]. Hepatocellular adenoma has also been described in patients taking anabolic androgenic steroids [3] and in those with some inherited metabolic disorders, as type 1 glycogen storage disease [4, 5]. Hepatocellular adenoma is a benign proliferation of hepatocytes in an otherwise normal liver and it constitutes 0.6% of all liver tumours [1‐3]. …
Literature
1.
de Buy M, Wenniger L, Terpstra V, Beuers U (2010) Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg 27(1):24–31CrossRef
2.
Rooks JB, Ory HW, Ishak KG et al (1979) Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 242(7):644–648PubMedCrossRef
3.
Socas L, Zumbado M, Pérez-Luzardo O et al (2005) Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 39(5):27CrossRef
4.
Oshita A, Itamoto T, Amano H et al (2008) Perioperative management of benign hepatic tumors in patients with glycogen storage disease type Ia. J Hepatobiliary Pancreat Surg 15(2):200–203PubMedCrossRef
5.
Resnick MB, Kozakewich HP, Perez-Atayde AR (1995) Hepatic adenoma in the pediatric age group. Clinicopathological observations and assessment of cell proliferative activity. Am J Surg Pathol 19(10):1181–1190PubMedCrossRef
6.
Levy RH, Mattson RH, Meldrum BS et al (2002) Antiepileptic drugs, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 528–540
7.
Clemmesen J, Hjalgrim-Jensen S (1978) Is phenobarbital carcinogenic? A follow-up of 8078 epileptics. Ecotoxicol Environ Saf 1(4):457–470PubMedCrossRef
8.
Clemmesen J, Hjalgrim-Jensen S (1981) Does phenobarbital cause intracranial tumors? A follow-up through 35 years. Ecotoxicol Environ Saf 5(2):255–260PubMedCrossRef
9.
White SJ, McLean AE, Howland C (1979) Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy. Lancet 2(8140):458–461PubMedCrossRef
10.
Olsen JH, Boice JD Jr, Jensen JP, Fraumeni JF Jr (1989) Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst 81(10):803–808PubMedCrossRef
11.
Olsen J, Wallin H, Boice JD Jr et al (1993) Phenobarbital, drug metabolism, and human cancer. Cancer Epidemiol Biomarkers Prev 2(5):449–452PubMed
12.
Lamminpää A, Pukkala E, Teppo L, Neuvonen PJ (2002) Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients. Eur J Clin Pharmacol 58(2):137–141PubMedCrossRef
13.
Peraino C, Fry RJ, Staffeldt E (1971) Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene. Cancer Res 31(10):1506–1512PubMed
14.
Driver HE, McLean AE (1986) Dose–response relationships for initiation of rat liver tumours by diethylnitrosamine and promotion by phenobarbitone or alcohol. Food Chem Toxicol 24(3):241–245PubMedCrossRef
15.
Diwan BA, Rice JM, Nims RW et al (1988) P-450 enzyme induction by 5-ethyl-5-phenylhydantoin and 5,5-diethylhydantoin, analogues of barbiturate tumor promoters phenobarbital and barbital, and promotion of liver and thyroid carcinogenesis initiated by N-nitrosodiethylamine in rats. Cancer Res 48(9):2492–2497PubMed
16.
Singh G, Driever PH, Sander JW (2005) Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 128(Pt 1):7–17PubMed
17.
Lautz TB, Finegold MJ, Chin AC, Superina RA (2008) Giant hepatic adenoma with atypical features in a patient on oxcarbazepine therapy. J Pediatr Surg 43(4):751–754PubMedCrossRef
18.
Seki A, Inoue T, Maegaki Y et al (2006) Polycystic ovary syndrome and hepatocellular adenoma related to long-term use of sodium valproate in a young woman. No To Hattatsu 38(3):205–208PubMed
19.
Tazawa K, Yasuda M, Ohtani Y et al (1999) Multiple hepatocellular adenomas associated with long-term carbamazepine. Histopathology 35(1):92–94PubMedCrossRef
20.
Rignall B, Braeuning A, Buchmann A, Schwarz M (2011) Tumor formation in liver of conditional β-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis 32(1):52–57PubMedCrossRef
21.
Phillips JM, Goodman JI (2009) Multiple genes exhibit phenobarbital-induced constitutive active/androstane receptor-mediated DNA methylation changes during liver tumorigenesis and in liver tumors. Toxicol Sci 108(2):273–289PubMedCrossRef
22.
Phillips JM, Burgoon LD, Goodman JI (2009) Phenobarbital elicits unique, early changes in the expression of hepatic genes that affect critical pathways in tumor-prone B6C3F1 mice. Toxicol Sci 109(2):193–205PubMedCrossRef
23.
Klaunig JE (1993) Selective induction of DNA synthesis in mouse preneoplastic and neoplastic hepatic lesions after exposure to phenobarbital. Environ Health Perspect 101(Suppl 5):235–239PubMedCrossRef
24.
Hyman GA, Sommers SC (1966) The development of Hodgkin's disease and lymphoma during anticonvulsant therapy. Blood 28(3):416–427PubMed
25.
26.
Vázquez JJ, Marigil MA (1989) Liver-cell adenoma in an epileptic man on barbiturates. Histol Histopathol 4(3):301–303PubMed
27.
Ferko A, Bedrna J, Nozicka J (2003) Pigmented hepatocellular adenoma of the liver caused by long-term use of phenobarbital. Rozhl Chir 82(4):192–195PubMed
28.
Warner KA, Fernstrom MJ, Ruch RJ (2003) Inhibition of mouse hepatocyte gap junctional intercellular communication by phenobarbital correlates with strain-specific hepatocarcinogenesis. Toxicol Sci 71(2):190–197PubMedCrossRef
29.
Michelucci R (2006) Optimizing therapy of seizures in neurosurgery. Neurology 67(12 Suppl 4):S14–S18PubMedCrossRef
Metadata
Title
Hepatocellular adenoma associated with long-term exposure to phenobarbital: a paediatric case report
Authors
Caterina Cerminara
Valentina Bagnolo
Francesco De Leonardis
Antonella Coniglio
Denis Roberto
Eliana Compagnone
Paolo Curatolo
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Child's Nervous System / Issue 6/2012
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-011-1636-1

Other articles of this Issue 6/2012

Child's Nervous System 6/2012 Go to the issue

Original Paper

Expression of AMPA receptor subunits in hippocampus after status convulsion

Original Paper

Adult outcome of pediatric hydrocephalus

Original Paper

The efficacy of silver-embedded polypropylene-grafted polyethylene glycol-coated ventricular catheters on prevention of shunt catheter infection in rats

Case Report

Two pathogenic NF1 gene mutations identified in DNA from a child with mild phenotype

Case Report

Interdisciplinary endoscopic assisted surgery of a patient with a complete transorbital intracranial impalement through the dominant hemisphere

Case Report

Multicystic encephalopathy following prolonged hypoxic ischemic insult—a case report